Richard Pulik Sells 406,731 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CFO Richard Pulik sold 406,731 shares of the firm’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $22.43, for a total transaction of $9,122,976.33. Following the sale, the chief financial officer directly owned 239,413 shares of the company’s stock, valued at $5,370,033.59. The trade was a 62.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Roivant Sciences Price Performance

ROIV opened at $21.63 on Wednesday. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $23.47. The stock has a market capitalization of $15.04 billion, a PE ratio of -38.63 and a beta of 1.22. The firm’s fifty day moving average price is $20.73 and its 200 day moving average price is $15.67.

Institutional Trading of Roivant Sciences

Several hedge funds have recently made changes to their positions in ROIV. Jones Financial Companies Lllp grew its stake in Roivant Sciences by 226.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after buying an additional 1,148 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after acquiring an additional 583 shares during the period. Bessemer Group Inc. boosted its holdings in shares of Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the period. CWM LLC grew its position in shares of Roivant Sciences by 44.6% during the second quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after acquiring an additional 920 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd increased its holdings in shares of Roivant Sciences by 75.8% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company’s stock worth $67,000 after acquiring an additional 1,900 shares during the period. Institutional investors own 64.76% of the company’s stock.

Analysts Set New Price Targets

ROIV has been the subject of a number of research reports. Citigroup lifted their price target on Roivant Sciences from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. HC Wainwright lifted their target price on Roivant Sciences from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. JPMorgan Chase & Co. boosted their price target on Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Thursday, September 18th. The Goldman Sachs Group upped their price target on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, Leerink Partners lifted their price objective on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $25.19.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.